PANoptosis is a prominent feature of desmoplakin cardiomyopathy
The Journal of Cardiovascular Aging · 2022 · 3 (1) · 3
DOI: 10.20517/jca.2022.34 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Cardiovascular Aging, 2022. Verfasst von Melis Olcum und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cardiovascular Genetics, Institute of Molecular Medicine and Department of Medicine, University of Texas Health Sciences Center at Houston…. Die Arbeit wurde bisher 32-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute, Cancer Prevention and Research Institute of Texas.
Abstract (Originalsprache)
Introduction
Arrhythmogenic cardiomyopathy (ACM) is hereditary cardiomyopathy caused by pathogenic variants (mutations) in genes encoding the intercalated disc (ID), particularly desmosome proteins. ACM caused by mutations in the DSP gene encoding desmoplakin (DSP) is characterized by the prominence of cell death, myocardial fibrosis, and inflammation, and is referred to as desmoplakin cardiomyopathy.
Aim
The aim of this article was to gain insight into the pathogenesis of DSP cardiomyopathy. Methods and Results: The Dsp gene was exclusively deleted in cardiac myocytes using tamoxifen-inducible MerCreMer (Myh6-McmTam) and floxed Dsp (DspF/F) mice (Myh6-McmTam:DspF/F). Recombination was induced upon subcutaneous injection of tamoxifen (30 mg/kg/d) for 5 days starting post-natal day 14. Survival was analyzed by Kaplan-Meier plots, cardiac function by echocardiography, arrhythmias by rhythm monitoring, and gene expression by RNA-Seq, immunoblotting, and immunofluorescence techniques. Cell death was analyzed by the TUNEL assay and the expression levels of specific markers were by RT-PCR and immunoblotting. Myocardial fibrosis was assessed by picrosirius red staining of the myocardial sections, RT-PCR, and immunoblotting. The Myh6-McmTam:DspF/F mice showed extensive molecular remodeling of the IDs and the differential expression of ~10,000 genes, which predicted activation of KDM5A, IRFs, and NFκB and suppression of PPARGC1A and RB1, among others in the DSP-deficient myocytes. Gene set enrichment analysis predicted activation of the TNFα/NFκB pathway, inflammation, cell death programs, and fibrosis. Analysis of cell death markers indicated PANoptosis, comprised of apoptosis (increased CASP3, CASP8, BAD and reduced BCL2), necroptosis (increased RIPK1, RIPK3, and MLKL), and pyroptosis (increased GSDMD and ASC or PYCARD) in the DSP-deficient myocytes. Transcript levels of the pro-inflammatory and pro-fibrotic genes were increased and myocardial fibrosis comprised ~25% of the myocardium in the DSP-deficient hearts. The Myh6-McmTam:DspF/F mice showed severe cardiac systolic dysfunction and ventricular arrhythmias, and died prematurely with a median survival rate of ~2 months.
Conclusion
The findings identify PANoptosis as a prominent phenotypic feature of DSP cardiomyopathy and set the stage for delineating the specific molecular mechanisms involved in its pathogenesis. The model also provides the opportunity to test the effects of pharmacological and genetic interventions on myocardial fibrosis and cell death. One sentence summary: Post-natal homozygous deletion of the Dsp gene leads to fulminant PANoptosis and severe myocardial fibrosis, cardiac dysfunction, arrhythmias, and premature death in mice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Cardiovascular Genetics, Institute of Molecular Medicine and Department of Medicine, University of Texas Health Sciences Center at Houston, Houston, TX 77030, USA.
- Heart Center & Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
- Center for Precision Health, School of Biomedical Informatics and School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
ORCID-Profile: Melis Olcum, Leila Rouhi, Maya M Gonzales, Hyun-Hwan Jeong, Zhongming Zhao, Priyatansh Gurha, Ali J Marian
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
- Cancer Prevention and Research Institute of Texas
Zitieren
APA
Olcum, M., Rouhi, L., Fan, S., Gonzales, M. M., Jeong, H. H., Zhao, Z., Gurha, P., & Marian, A. J. (2022). PANoptosis is a prominent feature of desmoplakin cardiomyopathy. The Journal of Cardiovascular Aging, 3(1), 3. https://doi.org/10.20517/jca.2022.34
Vancouver
Olcum M, Rouhi L, Fan S, Gonzales MM, Jeong HH, Zhao Z, et al. PANoptosis is a prominent feature of desmoplakin cardiomyopathy. The Journal of Cardiovascular Aging. 2022;3(1):3. doi:10.20517/jca.2022.34
BibTeX
@article{Olcum2022,
author = {Olcum, Melis and Rouhi, Leila and Fan, Siyang and Gonzales, Maya M and Jeong, Hyun-Hwan and Zhao, Zhongming and Gurha, Priyatansh and Marian, Ali J},
title = {PANoptosis is a prominent feature of desmoplakin cardiomyopathy},
journal = {The Journal of Cardiovascular Aging},
year = {2022},
volume = {3},
number = {1},
pages = {3},
doi = {10.20517/jca.2022.34}
}
EUVIMED